Solvotrin Therapeutics Limited

The Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin

Solvotrin Innovations Limited

The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth, Near Dublin

The Provost Fellows Foundation Scholars and the Other Members of Board of the College of the Holy and Undivided Trinity of Queen Elizabeth

John Francis Gilmer

Mark Ledwidge

Pat O'Flynn

Michael Whelehan

Jun Wang

Ken McDonald

Kate O'Donnell

Radics Gabor

Shona Harmon

Marek Radomski

Carlos Medina Martin

Louise Clune-Moriarty

Gabor Radics

Maeve Lally

Francis Quilty

Compositions containing iron and denatured protein have been prepared that are capable of increasing serum iron and other divalent metal cations in a subject. For example, edible microbeads have been prepared containing iron entrapped within a protein matrix that provides a gastroprotective effect and improves iron bioavailability relative to previously known vehicles for delivering iron to a subject.

Compositions and methods for increasing iron intake in a mammal

Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Feform and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.

Compounds and pharmaceutical compositions for use in the treatment of psoriasis are disclosed. Preferred compounds have demonstrated efficacy in reducing skin scaling, erythema and skin thickness in the mouse model of Aldara-induced psoriasis.

Compounds and compositions for use in treating psoriasis

A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C-Calkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, &#x2014;Cl, &#x2014;Br, a C-Calkyl, benzyl, a C-Calkoxy, benzyloxy, &#x2014;NHC(O)R, &#x2014;NH, &#x2014;NO, &#x2014;ONO, &#x2014;(CH)ONO, &#x2014;OC(O)[(CH)m], cyclic ONO, &#x2014;OCOArONO, &#x2014;OCOAr(CH)ONOor a C-Chaloalkyl ester, wherein R is a C-Calkyl or a C-Calkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.

Compounds with super-aspirin effects

A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.

Compounds for treatment of heart failure

The present invention relates to compounds, and compositions, useful for treating dyslipidemia.

Treatment for dyslipidemia

Growing community of inventors

Dublin, Ireland

John Francis Gilmer